Press releases
- Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
- Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
- Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
- Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
- Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
- Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
More ▼
Key statistics
As of last trade, Satellos Bioscience Inc (0ITA:FRA) traded at 0.284, 69.05% above the 52 week low of 0.168 set on Nov 14, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.284 |
---|---|
High | 0.284 |
Low | 0.284 |
Bid | 0.314 |
Offer | 0.35 |
Previous close | 0.286 |
Average volume | 818.86 |
---|---|
Shares outstanding | 112.79m |
Free float | 98.73m |
P/E (TTM) | -- |
Market cap | 53.58m CAD |
EPS (TTM) | -0.1718 CAD |
Data delayed at least 15 minutes, as of Jul 29 2024 07:04 BST.
More ▼